Yasu is a brand under Zhien Biotechnology Co., Ltd. (formerly Chongqing Zhien Pharmaceutical Co., Ltd.).

Zhien Biotechnology Co., Ltd. was founded in 2001 and is a national high-tech enterprise. The company focuses on building a full life cycle management service system for drugs, with MAH (Drug Marketing Authorization Holder) as the core, and compliant management and key technical service capabilities in the entire process of drug research and development, manufacturing, transaction promotion, post-market research, etc. , supports the registration, marketing and commercial delivery of MAH drugs.

After 20 years of development, the company has been approved to establish the "Chongqing Chiral Drug Engineering Technology Research Center", "Chongqing New Drug Design Engineering Technology Research Center", and "Chongqing Postdoctoral Research Workstation"; and jointly build the country with Chongqing University. Level "National and Local Joint Engineering Research Center for Advanced Drug Manufacturing Technology". The industrial achievements that have been formed at present include: 33 new drug certificates, 51 production approval documents, 11 foreign invention patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India), and 36 domestic invention patents .

The company has created a research and development platform established by Liangjiang Drug, Liujiang Medicine and Lanjiang Medicine, and is represented by Geyi Pharmaceutical Clinical Research Center (BE/I Clinical Research Center that complies with the GCP standards of the National Medical Products Administration). To provide integrated services for drug research and development and drug clinical research. A CMO industrial service platform has been built with Changshou raw materials production base and Jinfeng preparation production base as the core. The Changshou raw materials production base covers an area of ​​82,000 square meters, and the Jinfeng Preparation production base covers an area of ​​49,000 square meters. The raw material drug production capacity exceeds 100 tons, and the preparation production line covers dosage forms such as constant-release and slow-release capsules, granules, tablets, etc.

The company focuses on the research, development, production and sales of drugs such as metabolic system, central nervous system, respiratory system and cardiovascular system, and has multiple domestic first imitation and exclusive products and multiple Sino-US dual-report varieties. Among them, the total sales of orlistat capsule brands such as "Yasu" exceeded 1.4 billion yuan; Donepipirazine hydrochloride tablets are the winning products of the second batch of national medical insurance procurement, and other varieties (methanestone granules, ropinirole hydrochloride tablets) It also has good market performance. At the same time, the company actively expands the integration of new retail and traditional retail industries.

In order to accelerate the layout in the entire pharmaceutical industry, the company has built three major support platforms with the main line of "International Advanced Manufacturing Capacity + Non-profit Research and Evaluation Organization + Biomedical Transformation Special Fund" and actively promotes international leading enterprises in the field of biopharmaceuticals. The manufacturing of antibody and recombinant protein drugs jointly developed by South Korea's BINEX company, the biotechnology training center and pilot platform jointly developed by Cytiva Situfan (formerly GE Medical Life Sciences Division), and the research and development and pharmaceuticals introduced in cooperation with outstanding domestic companies. Technology, etc., help realize the industrialization of high-value pharmaceutical products such as large-molecular drugs, cell therapy and modern Chinese medicine represented by antibody drugs and new vaccines in Chongqing, and quickly improve the high-level development of the local pharmaceutical industry.

Wood is straight from the heart, and planting medicine is the benevolence. Zhien Biological will focus on building a full life cycle management service system for drugs, with MAH as the core, provide more professional, more efficient and more trustworthy services, create better drugs, and meet the public's pursuit of life and health.